NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

According to the American Brain Tumor Association, glioblastomas represent about 14% of all primary brain tumours, with ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

A clinical trial of an experimental cell therapy shows promising results for glioblastoma patients, with tumors disappearing ...

The tumor, which occurs when supportive cells in the brain grow and divide uncontrollably, is extremely aggressive and deadly. Most patients survive only 14 to 16 months after diagnosis.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical ...

Man with deadly glioblastoma shows no signs of disease after taking experimental immunotherapy drug ipilimumab, inspiring a ...

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Glioblastoma is an aggressive brain cancer can affect anyone, at any age, and comes with a poor prognosis. Couple shares symptoms that led to his diagnosis at 38.

Glioblastoma is the same cancer that killed Massachusetts Senator Ted Kennedy. It's different from the more treatable form of cancer that former President Jimmy Carter had -- a melanoma that ...